Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. CGRP in rat mesenteric artery and vein - receptor expression, CGRP presence and potential roles

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The effects of CGRP in vascular tissue - Classical vasodilation, shadowed effects and systemic dilemmas

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Vancouver Declaration II on Global Headache Patient Advocacy 2019

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Expression of the CGRP Family of Neuropeptides and their Receptors in the Trigeminal Ganglion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

CGRP plays a major role in the pathophysiology of migraine. Concomitant, CGRP plays a role in endogenous neurovascular protection from severe vasoconstriction associated with e.g. cerebral or cardiac ischemia. The CGRP antagonistic antibodies Fremanezumab (TEVA Pharmaceuticals) and Erenumab (Novartis/Amgen) have successfully been developed for the prevention of frequent migraine attacks. Whereas these antibodies might challenge endogenous neurovasular protection during severe cerebral or coronary vasoconstriction, potential future therapeutic CGRP agonists might induce migraine-like headaches in migraineurs. In the current study segments of cerebral artery have been used to obtain mechanistic insight of the CGRP-neutralizing anti-body Fremanezumab in neurovascular regulation in vitro. The basilar artery was selected due to its relevance in subarachnoid hemorrhage (SAH). Erenumab is known to block the human CGRP receptor and Fremanezumab to neutralize both human and rat CGRP. Results confirmed that Erenumab does not block the rat CGRP receptor and that Fremanezumab inhibits the vasodilatory effect induced by both human CGRP, rat CGRP and the metabolically stable CGRP analog, SAX in rat basilar artery. Fremanezumab also inhibits the vasodilatory effect of capsaicin in constricted segments of basilar artery. Capsaicin is used as a pharmacological tool to induce secretion of endogenous perivascular CGRP and our studies confirm that the antibody reach the perivascular sensory synaptic cleft and blocks the vasodilatory response of released CGRP in the present in vitro model. Thus, CGRP neutralization might have the mechanistic potential to block vasoprotective responses to severe vasoconstriction provided they reach the site of action and Fremanezumab is an important tool for future investigations of the impact of CGRP physiology.

OriginalsprogEngelsk
Artikelnummer172726
TidsskriftEuropean Journal of Pharmacology
Vol/bind864
Sider (fra-til)172726
Antal sider6
ISSN0014-2999
DOI
StatusUdgivet - 1 dec. 2019

Bibliografisk note

Copyright © 2019 Elsevier B.V. All rights reserved.

ID: 58348787